Zevra Therapeutics Inc. Cash Flow-to-Debt Ratio
Zevra Therapeutics Inc. cash flow-to-debt ratio. Zevra Therapeutics Inc. (ZVRA) has a Cash Flow-to-Debt Ratio of 0.03x as of September 2025, meaning its operating cash flow of $4.71 Million could theoretically repay 0% of its total liabilities ($136.95 Million) in one year. Check ZVRA operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Zevra Therapeutics Inc. (2012–2024)
Cash flow-to-debt ratio of Zevra Therapeutics Inc. from 2012 to 2024. Historical debt coverage capacity for Zevra Therapeutics Inc. across 13 annual periods. Check how aggressively does Zevra Therapeutics Inc. reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Zevra Therapeutics Inc. Cash Flow-to-Debt Ratio by Year (2012–2024)
Zevra Therapeutics Inc. cash flow-to-debt ratio by year from 2012 to 2024. Year-by-year debt coverage analysis for Zevra Therapeutics Inc.. For the full cash flow conversion analysis, see Zevra Therapeutics Inc. operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.50x | $-69.67 Million | $138.46 Million | ▼ -65.7% |
| 2023 | -0.30x | $-33.53 Million | $110.46 Million | ▲ +34.8% |
| 2022 | -0.47x | $-18.72 Million | $40.22 Million | ▼ -126.0% |
| 2021 | 1.79x | $10.44 Million | $5.82 Million | ▲ +7276.5% |
| 2020 | -0.02x | $-1.94 Million | $77.62 Million | ▲ +91.1% |
| 2019 | -0.28x | $-23.74 Million | $84.96 Million | ▲ +51.9% |
| 2018 | -0.58x | $-54.20 Million | $93.31 Million | ▼ -93.0% |
| 2017 | -0.30x | $-33.10 Million | $109.97 Million | ▼ -4.7% |
| 2016 | -0.29x | $-29.77 Million | $103.58 Million | ▲ +6.6% |
| 2015 | -0.31x | $-20.27 Million | $65.84 Million | ▲ +20.3% |
| 2014 | -0.39x | $-14.67 Million | $38.02 Million | ▼ -138.2% |
| 2013 | -0.16x | $-4.33 Million | $26.70 Million | ▲ +87.0% |
| 2012 | -1.25x | $-4.43 Million | $3.56 Million | — |